MKI67 and neuroendocrine carcinoma: Patients classified as NEC with Ki67 < 55% had the same poor prognosis of a mOS of 11 months as NEC with Ki67 ≥ 55%, whereas the outcome in NET G3 was more favorable, with a mOS of 33 months.